A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

• Status: COMPLETED
• Trial end date: 2025-06-01

Summary

The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.

• Phase: PHASE1

Details

• Lead Sponsor: Enanta Pharmaceuticals, Inc
• Treatments: Carbamazepine; Fluconazole; Itraconazole; Quinidine